Impact of Brokerage Rating on Achillion Pharmaceuticals, Inc.(ACHN)

Many Achillion Pharmaceuticals, Inc.(ACHN) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Achillion Pharmaceuticals was Initiated by Ladenburg Thalmann on Feb 2, 2017 to Buy, Price Target of the shares are set at $10.

Company has reported several Insider transactions to the SEC, on Dec 23, 2016, Jason S Fisherman (director) purchased 10,000 shares at 3.96 per share price.On Dec 5, 2016, Martha E Manning (EVP, General Counsel) purchased 2,500 shares at 4.09 per share price.On Dec 5, 2016, Joseph Truitt (Chief Commercial Officer) purchased 3,500 shares at 4.06 per share price.

Achillion Pharmaceuticals Last issued its quarterly earnings results on Aug 4, 2016. The company reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.15.During the same quarter in the previous year, the company posted $-0.25 EPS.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1.67 by 9 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): 10 analysts have set the short term price target of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) at $9.15. The standard deviation of short term price target has been estimated at $3.77, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 16 and $5 respectively.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rose 2.53% or 0.11 points on Tuesday and made its way into the gainers of the day. After trading began at $4.36 the stock was seen hitting $4.47 as a peak level and $4.32 as the lowest level. The stock ended up at $4.46. The daily volume was measured at 1,006,688 shares. The 52-week high of the share price is $10.06 and the 52-week low is $3.78. The company has a market cap of $610 million.

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The companys proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.


Share this post

Leave a Reply